This is an observational, multicenter study to determine the prevalence of Cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts. Patients who are potentially eligible for study participation will be identified through a chart review of patients who were seen at each study site prior to that site's initiation, or by entering care at the site while the site is participating in the trial.
Cerebrotendinous Xanthomatosis (CTX)
The patient has a diagnosis of idiopathic bilateral cataracts.
Between the ages of 2 to 21 years at the time of diagnosis
The patient has a diagnosis of cataracts with known etiology other than CTX.
The patient has a diagnosis of CTX.
The patient has cataracts caused by cataractogenic treatments.
The patient has taken or is currently taking cholic acid or chenodeoxycholic acid.
The patient has participated in an interventional clinical trial in the past 30 days.
The patient and/or their parent/legal guardian, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
November 9, 2018
Primary Contact Information
Retrophin Medical Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: